Literature DB >> 8645280

The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro.

A S Bourinbaiar1, S Lee-Huang.   

Abstract

We examined the effect on anti-HIV proteins MAP30 and GAP31, from Momordica charantia and Gelonium multiflorum, on the infection and replication of Herpes Simplex Viruses (HSV). Human lung WI-38 fibroblasts cultured in the presence of tenfold dilutions of MAP30 or GAP31 were exposed to HSV and viral yield was measured at 24-48 hours by ELISA. The effective concentrations for 50% inhibitions (EC50) were 0.1-0.2 microM for HSV-2, and 0.3-0.5 microM for HSV-1 for MAP30 and GAP31, respectively. In comparison, the EC(50) for acyclovir (ACV), a commonly used anti-HSV drug, was 0.2 and 1.7 microM for HSV-2 and HSV-1, respectively. The cytotoxicity of all three antivirals was negligible and comparable. However, the antiherpetic activity of the plant proteins against acyclovir-resistant strains was two to three logs more potent than ACV. These results suggest that MAP30 and GAP31, previously shown to be active against HIV, may be useful for the therapy of herpesvirus infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645280     DOI: 10.1006/bbrc.1996.0334

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Plant products as antimicrobial agents.

Authors:  M M Cowan
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Ribosome inactivating proteins from plants inhibiting viruses.

Authors:  Inderdeep Kaur; R C Gupta; Munish Puri
Journal:  Virol Sin       Date:  2011-12-10       Impact factor: 4.327

3.  Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells.

Authors:  Jian-Ming Fan; Jun Luo; Jun Xu; Sha Zhu; Qiao Zhang; De-Fu Gao; Yu-Bao Xu; Gai-Ping Zhang
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

4.  Efficient genetic transformation of Momordica charantia L. by microprojectile bombardment.

Authors:  Muralikrishna Narra; Raghu Ellendula; Srinivas Kota; Bharathkumar Kalva; Yashodhara Velivela; Sadanandam Abbagani
Journal:  3 Biotech       Date:  2017-11-22       Impact factor: 2.406

Review 5.  Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

Authors:  Komal Raina; Dileep Kumar; Rajesh Agarwal
Journal:  Semin Cancer Biol       Date:  2016-07-21       Impact factor: 15.707

6.  Analgesic and antipyretic activities of Momordica charantia Linn. fruits.

Authors:  Roshan Patel; Naveen Mahobia; Nitin Upwar; Naheed Waseem; Hetal Talaviya; Zalak Patel
Journal:  J Adv Pharm Technol Res       Date:  2010-10

7.  Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.

Authors:  Yao Meng; Shuangfeng Liu; Juan Li; Yanfa Meng; Xiaojun Zhao
Journal:  Int J Nanomedicine       Date:  2012-06-27

8.  Gene cloning and expression of MAP30 in Pichia pastoris.

Authors:  Fang Wang; Chun-Yu Chi; Li-Yuan Wang; Yu Qiao; Xiao-Xia Jin; Guo-Hua Ding
Journal:  Biotechnol Biotechnol Equip       Date:  2014-01-02       Impact factor: 1.632

9.  Momordica charantia Extract Induces Apoptosis in Human Cancer Cells through Caspase- and Mitochondria-Dependent Pathways.

Authors:  Chia-Jung Li; Shih-Fang Tsang; Chun-Hao Tsai; Hsin-Yi Tsai; Jong-Ho Chyuan; Hsue-Yin Hsu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-04       Impact factor: 2.629

10.  Antiviral Protein of Momordica charantia L. Inhibits Different Subtypes of Influenza A.

Authors:  Viroj Pongthanapisith; Kazuyoshi Ikuta; Pilaipan Puthavathana; Wichet Leelamanit
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.